EIGR News and Press, Eiger BioPharmaceuticals Inc. From 03/28/24

Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

2024-02-26 05:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan PR Newswire Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years...

2024-01-08 08:02:08 ET Empire Insurance Co (EIGR) announced stock split at a ratio of 1-for-30 on 2024-01-08 ... Full story available on KlickAnalytics.com

2024-01-04 10:11:49 ET More on Eiger BioPharmaceuticals Seeking Alpha’s Quant Rating on Eiger BioPharmaceuticals Historical earnings data for Eiger BioPharmaceuticals Financial information for Eiger BioPharmaceuticals For further details see: Eiger...

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split PR Newswire PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the devel...

2023-11-09 17:48:50 ET More on Eiger BioPharmaceuticals Eiger to stop late stage trial in hepatitis D patients, stock slumps ~36% after hours Seeking Alpha’s Quant Rating on Eiger BioPharmaceuticals For further details see: Eiger BioPharmaceuticals GAAP EP...

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delt...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...